Nephro-Urology Monthly

Published by: Kowsar

Bone Mineral Metabolism and Subsequent Hospitalization With Poor Quality of Life in Dialysis Patients

Zohreh Rostami 1 , Mahboobeh Sadat Hosseini 1 , * , Mahboob Lessan Pezeshki 2 , Farrokh Heidari 3 and Behzad Einollahi 1
Authors Information
1 Nephrology and Urology Research Center, Baqiyatallah University of Medical Sciences, Tehran, IR Iran
2 Department of Nephrology, Tehran University of Medical Sciences, Tehran, IR Iran
3 School of Medicine, Tehran University of Medical Sciences, Tehran, IR Iran
Article information
  • Nephro-Urology Monthly: January 01, 2014, 6 (1); e14944
  • Published Online: January 20, 2014
  • Article Type: Research Article
  • Received: September 20, 2013
  • Revised: October 12, 2013
  • Accepted: October 21, 2013
  • DOI: 10.5812/numonthly.14944

To Cite: Rostami Z, Hosseini M S, Lessan Pezeshki M, Heidari F, Einollahi B. Bone Mineral Metabolism and Subsequent Hospitalization With Poor Quality of Life in Dialysis Patients, Nephro-Urol Mon. 2014 ; 6(1):e14944. doi: 10.5812/numonthly.14944.

Abstract
Copyright © 2014, Nephrology and Urology Research Center. This is an open-access article distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (http://creativecommons.org/licenses/by-nc/4.0/) which permits copy and redistribute the material just in noncommercial usages, provided the original work is properly cited.
1. Background
2. Objectives
3. Patients and Methods
4. Results
5. Discussion
Acknowledgements
Footnotes
References
  • 1. Oliveira RB, Cancela ALE, Graciolli FG, Dos Reis LM, Draibe SA, Cuppari L, et al. Early control of PTH and FGF23 in normophosphatemic CKD patients: a new target in CKD-MBD therapy? Clin J Am Soci Nephrol 2010; 5(2): 286-91
  • 2. Chiu Y, Teitelbaum I, Misra M, de Leon EM, Adzize T, Mehrotra R. Pill burden, adherence, hyperphosphatemia, and quality of life in maintenance dialysis patients. Clin J Am Soci Nephrol 2009; 4(6): 1089-96
  • 3. Lessan-Pezeshki M, Rostami Z. Contributing factors in health-related quality of life assessment of ESRD patients: a single center study. Nephro Urol Mon 2009; 1(2): 129-36
  • 4. Pagels AA, Söderkvist BK, Medin C, Hylander B, Heiwe S. Health-related quality of life in different stages of chronic kidney disease and at initiation of dialysis treatment. Health Quality Life Outcome 2012; 10(1): 71[PubMed]
  • 5. Mapes DL, Lopes AA, Satayathum S, Mccullough KP, Goodkin DA, Locatelli F, et al. Health-related quality of life as a predictor of mortality and hospitalization: the Dialysis Outcomes and Practice Patterns Study (DOPPS). Kidney Int 2003; 64(1): 339-49
  • 6. Knight EL, Ofsthun N, Teng M, Lazarus JM, Curhan GC. The association between mental health, physical function, and hemodialysis mortality. Kidney Int 2003; 63(5): 1843-51
  • 7. Naves-Díaz M, Passlick-Deetjen J, Guinsburg A, Marelli C, Fernández-Martín JL, Rodríguez-Puyol D, et al. Calcium, phosphorus, PTH and death rates in a large sample of dialysis patients from Latin America. The CORES Study. Nephrol Dial Transplant 2011; 26(6): 1938-47
  • 8. Goodkin DA, Bragg-Gresham JL, Koenig KG, Wolfe RA, Akiba T, Andreucci VE, et al. Association of comorbid conditions and mortality in hemodialysis patients in Europe, Japan, and the United States: the Dialysis Outcomes and Practice Patterns Study (DOPPS). J Am Soci Nephrol 2003; 14(12): 3270-77
  • 9. Fouque D, Roth H, Pelletier S, London GM, Hannedouche T, Jean G, et al. Control of mineral metabolism and bone disease in haemodialysis patients: which optimal targets? Nephrol Dialysis Transplantation. 2013; 28(2): 360-7
  • 10. Pelletier S, Fouque D. Mineral and bone metabolism in dialysis: towards unified patient care? Nephrol Dial Transplant 2011; 26(1): 7-9
  • 11. Al Aly Z, González EA, Martin KJ, Gellens ME. Achieving K/DOQI laboratory target values for bone and mineral metabolism: an uphill battle. Am J Nephrol 2004; 24(4): 422-6
  • 12. Difficulties in achieving the K/DOQI practice guidelines for bone and mineral metabolism. Seminars in dialysis. : 171-4
  • 13. Johansen KL, Chertow GM. Chronic kidney disease mineral bone disorder and health-related quality of life among incident end-stage renal-disease patients. J Renal Nutr 2007; 17(5): 305-13
  • 14. Abe M, Okada K, Soma M. Mineral Metabolic Abnormalities and Mortality in Dialysis Patients. Nutrients. 2013; 5(3): 1002-23
  • 15. Moe S, Drüeke T, Cunningham J, Goodman W, Martin K, Olgaard K, et al. Definition, evaluation, and classification of renal osteodystrophy: a position statement from Kidney Disease: Improving Global Outcomes (KDIGO). Kidney Int 2006; 69(11): 1945-53
  • 16. Palmer SC, Hayen A, Macaskill P, Pellegrini F, Craig JC, Elder GJ, et al. Serum levels of phosphorus, parathyroid hormone, and calcium and risks of death and cardiovascular disease in individuals with chronic kidney disease a systematic review and meta-analysis. JAMA 2011; 305(11): 1119-27
  • 17. Young EW, Albert JM, Satayathum S, Goodkin DA, Pisoni RL, Akiba T, et al. Predictors and consequences of altered mineral metabolism: the Dialysis Outcomes and Practice Patterns Study. Kidney Int 2005; 67(3): 1179-87
  • 18. Melamed ML, Eustace JA, Plantinga L, Jaar BG, Fink NE, Coresh J, et al. Changes in serum calcium, phosphate, and PTH and the risk of death in incident dialysis patients: a longitudinal study. Kidney Int 2006; 70(2): 351-7
  • 19. Tanaka M, Yamazaki S, Hayashino Y, Fukuhara S, Akiba T, Saito A, et al. Hypercalcaemia is associated with poor mental health in haemodialysis patients: results from Japan DOPPS. Nephrol Dial Transplant 2007; 22(6): 1658-64
  • 20. Foley RN, Parfrey PS, Harrnett JD, Kent GM, Hu L, Dea R, et al. Hypocalcemia, morbidity, and mortality in end-stage renal disease. Am J Nephrol 1996; 16(5): 386-93
  • 21. Kalantar-Zadeh K, Kuwae N, Regidor DL, Kovesdy CP, Kilpatrick RD, Shinaberger CS, et al. Survival predictability of time-varying indicators of bone disease in maintenance hemodialysis patients. Kidney Int 2006; 70(4): 771-80
  • 22. Block GA, Klassen PS, Lazarus JM, Ofsthun N, Lowrie EG, Chertow GM. Mineral metabolism, mortality, and morbidity in maintenance hemodialysis. J Am Soci Nephrol 2004; 15(8): 2208-18
  • 23. Coco M, Rush H. Increased incidence of hip fractures in dialysis patients with low serum parathyroid hormone. Am J Kidney Dis 2000; 36(6): 1115-21
  • 24. Coen G, Ballanti P, Bonucci E, Calabria S, Costantini S, Ferrannini M, et al. Renal osteodystrophy in predialysis and hemodialysis patients: comparison of histologic patterns and diagnostic predictivity of intact PTH. Nephron. 2002; 91(1): 103-11
  • 25. Tentori F, Blayney MJ, Albert JM, Gillespie BW, Kerr PG, Bommer J, et al. Mortality risk for dialysis patients with different levels of serum calcium, phosphorus, and PTH: the Dialysis Outcomes and Practice Patterns Study (DOPPS). Am J Kidney Dis 2008; 52(3): 519-30
  • 26. Dhingra R, Sullivan LM, Fox CS, Wang TJ, D'Agostino Sr RB, Gaziano JI, et al. Relations of serum phosphorus and calcium levels to the incidence of cardiovascular disease in the community. Arch Int Med 2007; 167(9): 879-85[PubMed]
  • 27. Abramowitz M, Muntner P, Coco M, Southern W, Lotwin I, Hostetter TH, et al. Serum alkaline phosphatase and phosphate and risk of mortality and hospitalization. Clin J Am Soci Nephrol 2010; 5(6): 1064-71
  • 28. Foley RN, Collins AJ, Herzog CA, Ishani A, Kalra Philip A. Serum phosphorus levels associate with coronary atherosclerosis in young adults. J Am Soci Nephrol 2009; 20(2): 397-404
  • 29. Lacson Jr E, Wang W, Hakim RM, Teng M, Lazarus JMI. Associates of mortality and hospitalization in hemodialysis: potentially actionable laboratory variables and vascular access. Am J Kidney Dis 2009; 53(1): 79-90
  • 30. Horowitz MC, Bothwell ALM, Hesslein DGT, Pflugh DL, Schatz DG. B cells and osteoblast and osteoclast development. Immunologic Rev 2005; 208(1): 141-53
  • 31. Germin-Petrovic D, Mesaros-Devcic I, Lesac A, Mandic M, Soldatic M, Vezmar D, et al. Health-related quality of life in the patients on maintenance hemodialysis: the analysis of demographic and clinical factors. Coll Antropol. 2011; 35(3): 687-93[PubMed]
  • 32. Lowrie EG, Lew NL. Death risk in hemodialysis patients: the predictive value of commonly measured variables and an evaluation of death rate differences between facilities. Am J Kidney Dis 1990; 15(5): 458-82
  • 33. Lowrie EG, Lew NL. Commonly measured laboratory variables in hemodialysis patients: relationships among them and to death risk. Semin Nephrol. 1992; 12(3): 276-83
  • 34. Berger EE, Lowrie EG. Mortality and the length of dialysis. JAMA 1991; 265(7): 909-10
  • 35. Bloembergen WE, Stannard DC, Port FK, Wolfe RA, Pugh JA, Jones Camille A, et al. Relationship of dose of hemodialysis and cause-specific mortality. Kidney Int 1996; 50(2): 557-65
  • 36. Jean G, Bresson E, Terrat J, Vanel T, Hurot J, Lorriaux C, et al. Peripheral vascular calcification in long-haemodialysis patients: associated factors and survival consequences. Nephrol Dial Transplant 2009; 24(3): 948-55
  • 37. Chertow GM, Johansen KL, Lew N, Lazarus JM, Lowrie EG. Vintage, nutritional status, and survival in hemodialysis patients. Kidney Int 2000; 57(3): 1176-81
Creative Commons License Except where otherwise noted, this work is licensed under Creative Commons Attribution Non Commercial 4.0 International License .

Search Relations:

Author(s):

Article(s):

Create Citiation Alert
via Google Reader

Readers' Comments